The secondary objectives are to assess the anti-tumor efficacy and the in vivo persistence of adoptively transferred 4H11-28z/fIL-12/EFGRt T cells and finally to assess whether infusion of modified T cells enhances expansion of endogenous tumor-targeted T cells. This evidence concerns the gene SPRR2A and neoplasm.